198084-12-7

Basic information

• Product Name: 4-(PYRIMIDIN-5-YL)BENZALDEHYDE
• Synonyms: 4-(PYRIMIDIN-5-YL)BENZALDEHYDE;5-(4-FORMYLPHENYL)PYRIMIDINE;4-(5-PYRIMIDINYL)BENZALDEHYDE;AKOS BAR-0648;4-(2-(Dimethylamino)pyrimidin-5-yl)benzaldehyde;4-(2-Chloropyrimidin-5-yl)benzaldehyde;4-PYRIMIDIN-5-YL-BENZALDEHYDE, 95+%
• CAS NO: 198084-12-7
• Molecular Formula: C₁₁H₈N₂O
• Molecular Weight: 184.19
• Mol File: 198084-12-7.mol
• Article Data: 14

Chemical Properties

• Melting Point: 145-149 °C(lit.)
• Boiling Point: 369.1 °C at 760 mmHg
• Flash Point: 180.6 °C
• Appearance: /
• Density: 1.205 g/cm³
• Vapor Pressure: 1.21E-05mmHg at 25°C
• Refractive Index: 1.621
• PKA: 1.52±0.10(Predicted)
• CAS DataBase Reference: 4-(PYRIMIDIN-5-YL)BENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PYRIMIDIN-5-YL)BENZALDEHYDE(198084-12-7)
• EPA Substance Registry System: 4-(PYRIMIDIN-5-YL)BENZALDEHYDE(198084-12-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 198084-12-7(Hazardous Substances Data)

Usage

Uses

4-(Pyrimidin-5-yl)benzaldehyde is a useful reactant and reagent in organic reactions such as the synthesis of 1,?2-?difluorination of alkenes, and β-?Cyanoacrylamides.

InChI:InChI=1/C11H8N2O/c14-7-9-1-3-10(4-2-9)11-5-12-8-13-6-11/h1-8H

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 87199-16-4 3-Formylphenylboronic acid 
• 2036-41-1 5-methylpyrimidine 
• 87199-17-5 4-formylphenylboronic acid, 
• 503176-52-1 5-chloropyrimidine hydrochloride 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1115090-38-4 4-(3',5'-C₄H₃N₂)C₆H₄CHNCH₂CH₂NMe₂ 
• 1186485-07-3 4-(pyrimidin-5-yl)benzyl methanesulfonate 
• 1584164-92-0 4'-[4-(pyrimidin-5-yl)phenyl]-4,4':6',2-terpyridine 
• 1458054-21-1 5-(4-ethynylphenyl)pyrimidine 
• 1458054-84-6 4-((4-(4-(4-(pyrimidin-5-yl)phenyl)-1H-1,2,3-triazol-1-yl)-phenyl)sulfonyl)-N-((tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-4-carboxamide 
• 1458054-46-0 N-hydroxy-4-((4-(4-(4-( pyrimidin-5-yl)phenyl )-1H-1,2,3-triazol-1-yl)phenyl)sulfonyl)tetrahydro-2H-pyran-4-carboxamide hydrochloride 
• 1428968-32-4 1-(1H-indol-3-yl)-2-((3-methoxyphenyl)amino)-2-(4-(pyrimidin-5-yl)phenyl)ethanone 
• 1392419-34-9 C₂₇H₁₆F₃N₃O₃ 

Relevant articles and documents

Synthesis of zwitterionic palladium complexes and their application as catalysts in cross-coupling reactions of aryl, heteroaryl and benzyl bromides with organoboron reagents in neat water

N-(3-Chloro-2-quinoxalinyl)-N′-arylimidazolium salts (aryl = 2,6-diisopropylphenyl [HL1Cl]Cl, aryl = mesityl [HL2Cl]Cl) have been synthesized by treating 2,3-dichloroquinoxaline with the corresponding N′-arylimidazole in neat water. Facile reactions of these imidazolium salts with Pd(PPh3)4 and Pd2(dba)3/PPh3 (dba = dibenzyledene acetone) at 50 °C have afforded zwitterionic palladium(ii) complexes [Pd(HL1)(PPh3)Cl2] (I) and [Pd(HL2)(PPh3)Cl2] (II) in excellent yields. I and II have been tested for their ability to catalyze Suzuki-Miyaura cross coupling (SMC) reactions in neat water/K2CO3 and are found to be highly active for carrying out these reactions between aryl bromides and organoboron reagents. Furthermore, the scope of the catalyst I was also examined by employing (hetero)aryl bromides, hydrophilic aryl bromides, benzyl bromides and various organoboron reagents. More than 80 aryl/benzyl bromide-arylboronic acid combinations were screened in neat water/K2CO3 and it was found that I was a versatile catalyst, which produced biaryls/diarylmethanes in excellent yields. A TON of 82 000 was achieved by using I. Studies on the mechanism have also been carried out to investigate the involvement of carbene complexes in the catalytic path. Poison tests and a two-phase test were also conducted and the results are reported.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.